Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension
- PMID: 20725057
- PMCID: PMC2941699
- DOI: 10.1038/ajh.2010.98
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension
Abstract
Background: Age and race categories or renin profiling have been recommended to predict blood pressure responses to monotherapy with a beta-blocker or thiazide diuretic. Whether these or other characteristics predict blood pressure responses when the drugs are administered as add-on therapy is uncertain.
Methods: We evaluated predictors of blood pressure response in 363 men and women < or =65 years of age with primary hypertension (152 blacks, 211 whites), 86 of whom (24%) were untreated and 277 of whom (76%) were withdrawn from previous antihypertensive drugs before randomization to either atenolol followed by addition of hydrochlorothiazide (N = 180) or hydrochlorothiazide followed by addition of atenolol (N = 183). Responses were determined by home blood pressure averages before and after each drug administration. Race, age, plasma renin activity, and other characteristics including pretreatment blood pressure levels were incorporated into linear regression models to quantify their contributions to prediction of blood pressure responses.
Results: Plasma renin activity and pretreatment blood pressure level consistently contributed to prediction of systolic and diastolic responses to each drug administered as mono- and as add-on therapy. Higher plasma renin activity was consistently associated with greater blood pressure responses to atenolol and lesser responses to hydrochlorothiazide. The predictive effects of plasma renin activity were statistically independent of race, age, and other characteristics.
Conclusions: Plasma renin activity and pretreatment blood pressure level predict blood pressure responses to atenolol and hydrochlorothiazide administered as mono- and as add-on therapy in men and women < or =65 years of age.
Conflict of interest statement
Disclosure: The authors declared no conflict of interest.
Figures



Comment in
-
Heterogeneity of blood pressure response to therapy.Am J Hypertens. 2010 Sep;23(9):926-8. doi: 10.1038/ajh.2010.139. Am J Hypertens. 2010. PMID: 20733564 No abstract available.
-
Renin-guided treatment of hypertension: time for action.Am J Hypertens. 2010 Sep;23(9):929-30. doi: 10.1038/ajh.2010.135. Am J Hypertens. 2010. PMID: 20733565 No abstract available.
Similar articles
-
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.Hypertension. 2007 Feb;49(2):276-84. doi: 10.1161/01.HYP.0000253780.36691.4f. Epub 2006 Dec 11. Hypertension. 2007. PMID: 17159081 Clinical Trial.
-
Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.Am J Hypertens. 2016 Oct;29(10):1186-94. doi: 10.1093/ajh/hpw067. Epub 2016 Jun 30. Am J Hypertens. 2016. PMID: 27365079 Free PMC article.
-
Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity.Cardiovasc Drugs Ther. 2012 Apr;26(2):145-55. doi: 10.1007/s10557-011-6365-x. Cardiovasc Drugs Ther. 2012. PMID: 22311004 Clinical Trial.
-
Treating essential hypertension. The first choice is usually a thiazide diuretic.Prescrire Int. 2014 Sep;23(152):215-20. Prescrire Int. 2014. PMID: 25325125 Review.
-
Thiazide and loop diuretics.J Clin Hypertens (Greenwich). 2011 Sep;13(9):639-43. doi: 10.1111/j.1751-7176.2011.00512.x. Epub 2011 Jul 27. J Clin Hypertens (Greenwich). 2011. PMID: 21896142 Free PMC article. Review.
Cited by
-
Renin Feedback Is an Independent Predictor of Outcome in HFpEF.J Pers Med. 2021 May 3;11(5):370. doi: 10.3390/jpm11050370. J Pers Med. 2021. PMID: 34063595 Free PMC article.
-
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.Eur J Pharm Sci. 2019 Apr 1;131:93-98. doi: 10.1016/j.ejps.2019.02.013. Epub 2019 Feb 10. Eur J Pharm Sci. 2019. PMID: 30753892 Free PMC article. Clinical Trial.
-
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.Circ Cardiovasc Genet. 2012 Dec;5(6):686-91. doi: 10.1161/CIRCGENETICS.112.964080. Epub 2012 Oct 19. Circ Cardiovasc Genet. 2012. PMID: 23087401 Free PMC article. Clinical Trial.
-
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.J Hypertens. 2015 Nov;33(11):2278-85. doi: 10.1097/HJH.0000000000000714. J Hypertens. 2015. PMID: 26425837 Free PMC article.
-
β1-adrenergic receptor polymorphisms: a possible genetic predictor of bisoprolol response in acute coronary syndrome.Future Sci OA. 2023 Aug 22;9(10):FSO895. doi: 10.2144/fsoa-2023-0113. eCollection 2023 Dec. Future Sci OA. 2023. PMID: 37753361 Free PMC article.
References
-
- Freis ED, Materson BJ, Flamenbaum V. Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. Am J Med. 1983;74:1029–1041. - PubMed
-
- Bidiville J, Nussberger J, Waeber G, Porchet M, Waeber B, Brunner HR. Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension. 1988;11:166–173. - PubMed
-
- Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914–921. - PubMed
-
- Materson BJ, Reda DJ, Preston RA, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R. Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med. 1995;155:1757–1762. - PubMed
-
- Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999;353:2008–2013. - PubMed